Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

442 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
Plage H, Furlano K, Hofbauer S, Weinberger S, Ralla B, Franz A, Fendler A, de Martino M, Roßner F, Elezkurtaj S, Kluth M, Lennartz M, Blessin NC, Marx AH, Samtleben H, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Hallmann S, Koch S, Adamini N, Zecha H, Minner S, Simon R, Sauter G, Weischenfeldt J, Klatte T, Schlomm T, Horst D, Schallenberg S. Plage H, et al. Among authors: schlomm t. BMC Urol. 2024 Apr 24;24(1):96. doi: 10.1186/s12894-024-01482-z. BMC Urol. 2024. PMID: 38658905 Free PMC article.
Molecular staging of prostate cancer in the year 2007.
Schlomm T, Erbersdobler A, Mirlacher M, Sauter G. Schlomm T, et al. World J Urol. 2007 Mar;25(1):19-30. doi: 10.1007/s00345-007-0153-z. Epub 2007 Mar 2. World J Urol. 2007. PMID: 17334767 Review.
Expression and prognostic relevance of annexin A3 in prostate cancer.
Köllermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H, Schrattenholz A. Köllermann J, et al. Among authors: schlomm t. Eur Urol. 2008 Dec;54(6):1314-23. doi: 10.1016/j.eururo.2008.01.001. Epub 2008 Jan 16. Eur Urol. 2008. PMID: 18222597
Molecular cancer phenotype in normal prostate tissue.
Schlomm T, Hellwinkel OJ, Buness A, Ruschhaupt M, Lübke AM, Chun FK, Simon R, Budäus L, Erbersdobler A, Graefen M, Huland H, Poustka A, Sültmann H. Schlomm T, et al. Eur Urol. 2009 Apr;55(4):885-90. doi: 10.1016/j.eururo.2008.04.105. Epub 2008 May 16. Eur Urol. 2009. PMID: 18501497
Clinical significance of p53 alterations in surgically treated prostate cancers.
Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A. Schlomm T, et al. Mod Pathol. 2008 Nov;21(11):1371-8. doi: 10.1038/modpathol.2008.104. Epub 2008 Jun 13. Mod Pathol. 2008. PMID: 18552821 Free article.
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A, Schlomm T, Huland H, Köllermann J, Simon P, Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A. Fleischmann A, et al. Among authors: schlomm t. Clin Cancer Res. 2008 Dec 1;14(23):7838-42. doi: 10.1158/1078-0432.CCR-08-1432. Clin Cancer Res. 2008. PMID: 19047112
442 results